Jasper Therapeutics (JSPR) Non-Current Deferred Tax Liability (2020 - 2023)
Jasper Therapeutics (JSPR) posted quarterly Non-Current Deferred Tax Liability of $488000.0 for Q4 2023, down 13.32% year-over-year from $563000.0 in Q4 2022, and down 13.32% quarter-over-quarter from $563000.0 in Q4 2022.
Jasper Therapeutics (JSPR) Non-Current Deferred Tax Liability (2020 - 2023) Analysis & Trends
Jasper Therapeutics' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $488000.0 for Q4 2023.
- In Q4 2023, Non-Current Deferred Tax Liability fell 13.32% year-over-year to $488000.0; the TTM figure through Dec 2023 stood at $488000.0 (down 13.32% YoY), while the FY2023 annual figure was $488000.0, down 13.32% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2023 stood at $488000.0, down from $563000.0 in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $563000.0 in Q4 2022, with the low at $323000.0 in Q4 2021.
- The 4-year median for Non-Current Deferred Tax Liability is $443500.0 (2020), against an average of $443250.0.
- The sharpest annual moves came in 2021 and 2022: Non-Current Deferred Tax Liability declined 19.05% in 2021, then soared 74.3% in 2022.
- Jasper Therapeutics' Non-Current Deferred Tax Liability stood at $399000.0 in 2020, then slipped by 19.05% to $323000.0 in 2021, then surged by 74.3% to $563000.0 in 2022, then decreased by 13.32% to $488000.0 in 2023.
- Business Quant data shows JSPR's Non-Current Deferred Tax Liability at $488000.0 in Q4 2023, $563000.0 in Q4 2022, and $323000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Jasper Therapeutics | 20.06 Mn | 20.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 488,000.00 |
| Dec 31, 2023 | 488,000.00 |
| Dec 31, 2022 | 563,000.00 |
| Dec 31, 2022 | 563,000.00 |
| Dec 31, 2021 | 323,000.00 |
| Dec 31, 2021 | 323,000.00 |
| Dec 31, 2020 | 399,000.00 |
| Dec 31, 2020 | 399,000.00 |